Inclusion Criteria:

        Eligibility is determined prior to blood collection . Patients must satisfy the following
        criteria to be enrolled in the study:

          1. Signed Informed Consent Form

          2. Male or female patients who are 12 - 75 years of age

          3. Histologically confirmed classical Hodgkin Lymphoma

          4. Relapsed or refractory cHL that has failed at least 3 prior lines of therapy,
             including:

               -  chemotherapy

               -  BV and/or

               -  PD-1 inhibitor Patients may have previously received an autologous and/or
                  allogeneic stem cell transplant

          5. CD30-positive tumor

          6. At least 1 measurable lesion according to The Lugano Classification

          7. Laboratory parameters: Hematological, renal and hepatic functions, and coagulation
             parameters

               -  Hgb ≥ 8.0 g/dL

               -  Total bilirubin ≤ 1.5 × ULN

               -  AST and ALT ≤ 5 × the ULN

               -  CrCl > 45 mL/min

               -  ANC >1,000/µL

               -  Platelets >75,000/µL

               -  PT or INR ≤ 1.5 × ULN; PTT or aPTT ≤ 1.5 × ULN

          8. ECOG PS of 0 to 1 or equivalent [either Karnofsky PS (for patients ≥ 16 year of age)
             or Lansky PS (for patients < 16 years of age)]

          9. Anticipated life expectancy > 12 weeks

        Exclusion Criteria:

          1. Evidence of lymphomatous involvement of central nervous system (CNS)

          2. Presence of clinically relevant or active seizure disorder, stroke, cerebrovascular
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with
             central nervous system (CNS) involvement

          3. Active uncontrolled bleeding or a known bleeding diathesis

          4. Inadequate pulmonary function defined as pulse oximetry < 90% on room air

          5. ECHO or MUGA with LVEF < 45%

          6. On-going treatment with immunosuppressive drugs or chronic systemic corticosteroids

          7. Having received:

               -  Anti-CD30 antibody-based therapy within 4 weeks prior to CD30.CAR-T infusion

               -  Prior investigational CD30.CAR-T

               -  CD30 bispecific agent within 8 weeks prior to CD30.CAR-T infusion

               -  Autologous HSCT within 90 days or allogeneic HSCT within 180 days prior to
                  CD30.CAR-T infusion

          8. Currently receiving any investigational agents within 4 weeks prior to study
             enrollment; or received any tumor vaccines within 6 weeks prior to CD30.CAR-T infusion

          9. Active acute or chronic graft versus host disease (GVHD) requiring immune suppression
             regardless of grade

         10. Evidence of human immunodeficiency virus (HIV) infection

         11. Seropositive for and with evidence of active viral infection with hepatitis B virus
             (HBV) or hepatitis C virus (HCV)

         12. Unresolved > Grade 1 non-hematologic toxicity associated with any prior treatments

         13. History of hypersensitivity reactions to murine protein-containing products or other
             product excipients

         14. Symptomatic cardiovascular disease: Class III or IV according to the New York Heart
             Association (NYHA) Functional Classification

         15. Active second malignancy or history of another malignancy within the last 3 years

         16. Women who are pregnant or intending to become pregnant; women who are breastfeeding;
             persons with procreative potential not using and not willing to use 2 highly effective
             methods of contraception

         17. Any other serious, life-threatening, or unstable preexisting medical conditions